68208-26-4

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL is used as a reactant for the synthesis of meta-?functionalized pyridines, which are important intermediates in the development of pharmaceutical compounds. These pyridines can be further modified to create a wide range of drugs with various therapeutic applications.
Used in Chemical Synthesis:
3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL is used as a versatile building block in the synthesis of various organic compounds, including heterocycles, amines, and other functionalized molecules. Its reactivity allows for the formation of a wide range of products, making it a valuable tool in organic chemistry.
Used in Research and Development:
3-AMINO-3-(4-CHLORO-PHENYL)-PROPAN-1-OL is used as a research compound in the development of new synthetic methods and the study of reaction mechanisms. Its unique properties and reactivity make it an interesting subject for academic and industrial research.

InChI:InChI=1/C9H12ClNO/c10-8-3-1-7(2-4-8)9(11)5-6-12/h1-4,9,12H,5-6,11H2

Upstream product

• 19947-39-8 3-amino-3-(4-chlorophenyl)propionic acid 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 886493-66-9 tert-butyl 1-(4-chlorophenyl)-3-hydroxypropylcarbamate 
• 1143534-27-3 3-(tert-butoxycarbonylamino)-3-(4-chlorophenyl)propyl Methanesulfonate 
• 1143535-59-4 tert-butyl 1-(4-chlorophenyl)-3-sulfamoylpropylcarbamate 
• 1143535-61-8 3-amino-3-(4-chlorophenyl)propane-1-sulfonamide 
• 1143534-29-5 tert-butyl 1-(4-chlorophenyl)-3-(dimethylamino)propylcarbamate 
• 885672-69-5 1-(4-chlorophenyl)-N³,N³-dimethylpropane-1,3-diamine 
• 1143535-51-6 tert-butyl 1-(4-chlorophenyl)-3-methoxypropylcarbamate 
• 1143535-53-8 1-(4-chlorophenyl)-3-methoxypropan-1-amine 
• 1143532-43-7 4-amino-N-(1-(4-chlorophenyl)-3-(dimethylamino)propyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-70-3 (S)-4-amino-N-(1-(4-chlorophenyl)-3-(dimethylamino)propyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-52-1 4-amino-N-(1-(4-chlorophenyl)-3-sulfamoylpropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 
• 1143533-50-9 4-amino-N-(1-(4-chlorophenyl)-3-methoxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 

Relevant academic research and scientific papers

Site-Specific C(sp3)–H Aminations of Imidates and Amidines Enabled by Covalently Tethered Distonic Radical Anions

The utilization of N-centered radicals to synthesize nitrogen-containing compounds has attracted considerable attention recently, due to their powerful reactivities and the concomitant construction of C?N bonds. However, the generation and control of N-centered radicals remain particularly challenging. We report a tethering strategy using SOMO-HOMO-converted distonic radical anions for the site-specific aminations of imidates and amidines with aid of the non-covalent interaction. This reaction features a remarkably broad substrate scope and also enables the late-stage functionalization of bioactive molecules. Furthermore, the reaction mechanism is thoroughly investigated through kinetic studies, Raman spectroscopy, electron paramagnetic resonance spectroscopy, and density functional theory calculations, revealing that the aminations likely involve direct homolytic cleavage of N?H bonds and subsequently controllable 1,5 or 1,6 hydrogen atom transfer.

Base-induced Sommelet–Hauser rearrangement of N-(α-(2-oxyethyl)branched)benzylic glycine ester-derived ammonium salts via a chelated intermediate

The base-induced Sommelet–Hauser (S–H) rearrangement of N-(α-branched)benzylic glycine ester-derived ammonium salts 1 was investigated. When the α-branched substituent was a simple alkyl, such as a methyl or butyl, desired S–H rearrangement product 2 was obtained in low yield with formation of the [1,2] Stevens rearranged 4 and Hofmann eliminated products 5 and 6. However, when the α-branched substituent had a 2-oxy moiety, such as 2-acetoxyethyl or 2-benzoyloxyethyl, the yields of 2 were improved. These results could be explained by formation of chelated intermediate C that stabilizes the carbanionic ylide, and the subsequent initial dearomative [2,3] sigmatropic rearrangement would be accelerated. The existence of C was supported by mechanistic experiments. This enhancement effect is not very strong or effective; however, it will expand the synthetic usefulness of ammonium ylide rearrangements.

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases

Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.

PYRROLO [2,3-D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS

The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I)